company background image
NVAX

Novavax NasdaqGS:NVAX Stock Report

Last Price

US$10.89

Market Cap

US$936.3m

7D

-3.0%

1Y

-88.1%

Updated

08 Feb, 2023

Data

Company Financials +

NVAX Stock Overview

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

NVAX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

New

Notes are coming soon

Novavax, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novavax
Historical stock prices
Current Share PriceUS$10.89
52 Week HighUS$95.34
52 Week LowUS$8.75
Beta1.72
1 Month Change-11.17%
3 Month Change-50.81%
1 Year Change-88.14%
3 Year Change48.97%
5 Year Change-73.18%
Change since IPO-86.39%

Recent News & Updates

Recent updates

COVID-19 remains global health emergency - WHO

Oct 19

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

Oct 10

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Oct 03

Novavax makes 1M doses of its COVID-19 vaccine available for use in the UK

Sep 27

EU clears Novavax's COVID-19 shot for use as a booster dose in adults

Sep 12

Novavax wins EU backing for COVID-19 booster shot

Sep 01

Novavax: Finding Its Niche

Aug 23

Novavax COVID vaccine gets provisional approval in New Zealand as booster shot

Aug 17

Novavax Q2: Time To Turn Bullish After The Massive Collapse

Aug 11

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Aug 11
Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Aug 03

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Jul 26

Serum Institute of India supplies Novavax's COVID vaccine in US

Jul 18

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Jul 11

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Jul 05

Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this week

Jun 29

Novavax seeks label expansion for COVID-19 shot in Canada

Jun 23

The Novavax Vaccine, Finally

Jun 08

Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?

May 24
Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?

Novavax: Buying Here Will Not End Well

May 18

Novavax: Don't Catch The Falling Knives

May 07

Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull Case

Apr 21

Novavax Stock Forecast: Where Is It Likely Heading By 2025?

Apr 05

Novavax: Disappointing Performance Despite Promises - Poor Outlook Ahead

Mar 30

Is Novavax Stock A Buy Or Sell As COVID-19 Shot Awaits FDA Approval?

Mar 04

Novavax Earnings Preview: Hold On Potential To Deliver Sizeable Vaccine Supply

Feb 24

Shareholder Returns

NVAXUS BiotechsUS Market
7D-3.0%-0.8%0.9%
1Y-88.1%3.9%-10.9%

Return vs Industry: NVAX underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: NVAX underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is NVAX's price volatile compared to industry and market?
NVAX volatility
NVAX Average Weekly Movement16.1%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: NVAX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19871,541John Jacobshttps://www.novavax.com

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.

Novavax, Inc. Fundamentals Summary

How do Novavax's earnings and revenue compare to its market cap?
NVAX fundamental statistics
Market CapUS$936.31m
Earnings (TTM)-US$1.32b
Revenue (TTM)US$1.85b

0.5x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NVAX income statement (TTM)
RevenueUS$1.85b
Cost of RevenueUS$2.66b
Gross Profit-US$814.59m
Other ExpensesUS$507.39m
Earnings-US$1.32b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-15.38
Gross Margin-44.11%
Net Profit Margin-71.59%
Debt/Equity Ratio-57.3%

How did NVAX perform over the long term?

See historical performance and comparison